Second vaccine with high immunity
Moderna / NIH vaccine
mRNA 1273
94.5%
https://www.businesswire.com/news/home/20201116005608/en/
https://www.nytimes.com/2020/11/16/health/Covid-moderna-vaccine.html
https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19
Pfizer / BioNTech, 90 %
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against
N = 43,538 participants
94 people infected so far
People catching COVID, starting 2 weeks after second shot
No data on disease severity
Food and Drug Administration, 50 % to be approved
Moderan trial
Double blind
4 weeks between shots
25,650 participants have received two shots
37 % from communities of color
42 % from populations high risk, (over 65 or diabetes, obesity, heart disease)
95 people contracted the virus, 11 of these had severe disuses
No children
Adolescents soon, moving on to children
Moderan vaccination group
5 people contracted coronavirus
Moderna control group (salty water)
90 people contracted coronavirus
11 of whom had severe disease
Differences between groups was highly significant
Results analyzed by independent data safety monitoring board (appointed by the National Institutes of Health)
Results were so strong; company felt an ethical obligation to offer the vaccine to the placebo group as soon as possible
Dr. Anthony Fauci
I had been saying I would be satisfied with a 75 % effective vaccine
Aspirationally, you would like to see 90, 95 %, but I wasn’t expecting it.
I thought we’d be good, but 94.5 percent is very impressive.
Both vaccines
More cases have acetated results
Studies continuing
Target the spike protein
Require 2 shots
Not found serious side effects
Sore arms, fatigue, fever and joint and muscle aches that last for a day or two
Vaccine storage and transport
Different formulations of lipid
Moderna
Minus 20’C (- 4 Fahrenheit)
Will last 30 days in the refrigerator
Ordinary freezer, six months
12 hours at room temperature
Pfizer
Minus 70’ C (- 94 Fahrenheit)
Roll out
Both about to apply for emergency FDA authorization
Roll out, Moderna
20 million doses ready by end of 2020
500 million to one billion doses in 2021
Manufacture in US, Switzerland, Spain
Two-month follow-up safety data, as (required by FDA), second half of November
i.e. watch trial subjects for two months after they receive a final dose for any side effects that may crop up
Then, will file for an emergency use authorization
Government authorising agencies, Britain, Canada, Europe
US, 100 million with options on 400 million more
EU, 80 million doses
Japan, 50 million doses
Canada, 20 million
Switzerland, 4.5 million
UK orders 5 million doses for spring
Qatar and Israel
In talks with the WHO, COVAX, distribution and a tiered pricing proposal
Roll out, Pfizer
50 million doses by end of 2020
US, 100 – 500 million doses
EU, 200 million doses
UK, 40 million doses
AZ / Oxford
EU, 400 million doses
UK, 100 million
Vaccines alliance for poorer countries, 300 million
Costs, Sanofi and GSK
Both expected to cost about £8 a dose
AZ / Oxford
£ 3 per dose
Costs, Moderna
US, government will buy, free to the public
US warp speed, already put in 2.5 billion, $24.80 a shot
Both companies making a profit
Moderna, overseas charge, $32 to $37 per dose
Probably about £42 per course
Costs, Pfizer
Operation Warp Speed has promised Pfizer $1.95 billion to provide 100 million doses
$19.50 per dose.
Unclear points
Age distribution of infections
Person to person reduction
How long immunity will last
Видео Second vaccine with high immunity канала Dr. John Campbell
mRNA 1273
94.5%
https://www.businesswire.com/news/home/20201116005608/en/
https://www.nytimes.com/2020/11/16/health/Covid-moderna-vaccine.html
https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19
Pfizer / BioNTech, 90 %
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against
N = 43,538 participants
94 people infected so far
People catching COVID, starting 2 weeks after second shot
No data on disease severity
Food and Drug Administration, 50 % to be approved
Moderan trial
Double blind
4 weeks between shots
25,650 participants have received two shots
37 % from communities of color
42 % from populations high risk, (over 65 or diabetes, obesity, heart disease)
95 people contracted the virus, 11 of these had severe disuses
No children
Adolescents soon, moving on to children
Moderan vaccination group
5 people contracted coronavirus
Moderna control group (salty water)
90 people contracted coronavirus
11 of whom had severe disease
Differences between groups was highly significant
Results analyzed by independent data safety monitoring board (appointed by the National Institutes of Health)
Results were so strong; company felt an ethical obligation to offer the vaccine to the placebo group as soon as possible
Dr. Anthony Fauci
I had been saying I would be satisfied with a 75 % effective vaccine
Aspirationally, you would like to see 90, 95 %, but I wasn’t expecting it.
I thought we’d be good, but 94.5 percent is very impressive.
Both vaccines
More cases have acetated results
Studies continuing
Target the spike protein
Require 2 shots
Not found serious side effects
Sore arms, fatigue, fever and joint and muscle aches that last for a day or two
Vaccine storage and transport
Different formulations of lipid
Moderna
Minus 20’C (- 4 Fahrenheit)
Will last 30 days in the refrigerator
Ordinary freezer, six months
12 hours at room temperature
Pfizer
Minus 70’ C (- 94 Fahrenheit)
Roll out
Both about to apply for emergency FDA authorization
Roll out, Moderna
20 million doses ready by end of 2020
500 million to one billion doses in 2021
Manufacture in US, Switzerland, Spain
Two-month follow-up safety data, as (required by FDA), second half of November
i.e. watch trial subjects for two months after they receive a final dose for any side effects that may crop up
Then, will file for an emergency use authorization
Government authorising agencies, Britain, Canada, Europe
US, 100 million with options on 400 million more
EU, 80 million doses
Japan, 50 million doses
Canada, 20 million
Switzerland, 4.5 million
UK orders 5 million doses for spring
Qatar and Israel
In talks with the WHO, COVAX, distribution and a tiered pricing proposal
Roll out, Pfizer
50 million doses by end of 2020
US, 100 – 500 million doses
EU, 200 million doses
UK, 40 million doses
AZ / Oxford
EU, 400 million doses
UK, 100 million
Vaccines alliance for poorer countries, 300 million
Costs, Sanofi and GSK
Both expected to cost about £8 a dose
AZ / Oxford
£ 3 per dose
Costs, Moderna
US, government will buy, free to the public
US warp speed, already put in 2.5 billion, $24.80 a shot
Both companies making a profit
Moderna, overseas charge, $32 to $37 per dose
Probably about £42 per course
Costs, Pfizer
Operation Warp Speed has promised Pfizer $1.95 billion to provide 100 million doses
$19.50 per dose.
Unclear points
Age distribution of infections
Person to person reduction
How long immunity will last
Видео Second vaccine with high immunity канала Dr. John Campbell
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Ivermectin or MolnupiravirCompared vaccine adverse effectsMr David Davis MP and Vitamin DMost common symptoms and immunityUS, UK and viral survival on skinEndocrine lesson 1, Introduction and pituitaryCoronavirus Mutations and COVID 19 Vaccine Implications with Shane Crotty, PhD (SARS CoV 2 Variants)Idaho crisis, Ivermectin clarificationMMR vaccine and COVID immunityTalking with Dr. KyawSputnik V peer reviewedLong term immunity, looking goodCovid-19: Update on Vaccines and Implications of the New VariantsIsrael special reportPandemic, mostly good newsCOVID 19 | VACUNA MODERNA FASE 3 | EFECTOS ADVERSOSLong term COVIDLong term COVIDViral origins and vaccine supplyKizzmekia Corbett: "Vaccines" (11/10/2020)